Corporate Board Profile
Tech Score: 38/100
5 mention(s) identify HEIDI HAGEN as having software/technology expertise.
| Company | Filing Date | Evidence | Reason |
|---|---|---|---|
| Vericel Corp | 2020-03-20 | Ms. Hagen earned a B.S. in cell and molecular biology, M.S. in bioengineering, and MBA at the University of Washington. Since October 2015, Ms. Hagen has served as Chief Strategy Officer for Vineti, Inc., a privately-held company that develops and sells cloud-based software platforms for ordering, manufacturing and delivering personalized medicines. | She has degrees in cell and molecular biology, bioengineering, and an MBA, and has worked as Chief Strategy Officer for a company developing cloud-based software platforms. |
| Vericel Corp | 2021-03-19 | Ms. Hagen earned a B.S. in cell and molecular biology, M.S. in bioengineering, and M.B.A. at the University of Washington. The Board of Directors believes Ms. Hagen’s qualifications to serve on our Board of Directors include her leadership roles in the biotechnology industry in a wide range of positions, as well as her expertise in manufacturing, quality and other technical operations in the biotechnology and pharmaceutical space. Additionally, since October 2015, Ms. Hagen has served as Co-founder and Advisor (formerly Chief Strategy Officer) for Vineti, Inc., a privately-held company that develops and sells cloud-based software platforms for ordering, manufacturing and delivering personalized medicines. | Holds a B.S. in cell and molecular biology, M.S. in bioengineering, and has experience as a biotechnology and pharmaceutical operations and technology consultant, including co-founding a company that develops cloud-based software platforms for personalized medicines. |
| Vericel Corp | 2022-03-17 | Ms. Hagen is also co-founder and former Chief Strategy Officer of Vineti, Inc., a software platform company for cell and gene therapy supply chain management. | Ms. Hagen has extensive experience in cell and gene therapy industries and co-founded a software platform company for cell and gene therapy supply chain management, indicating software-related technical skills. |
| Vericel Corp | 2024-03-21 | Co-founder and Advisor and former Chief Strategy Officer of Vineti, Inc., a software platform company for cell and gene therapy supply chain management (2015-present). She also has a B.S. in cell and molecular biology, M.S. in bioengineering, and M.B.A. | Ms. Hagen has extensive product development and leadership experience in biopharmaceutical and medical device industries, including co-founding and advising a software platform company for cell and gene therapy supply chain management. |
| Vericel Corp | 2025-03-20 | B.S. in cell and molecular biology, M.S. in bioengineering; Co-founder and Advisor and former Chief Strategy Officer of Vineti, Inc., a software platform company for cell and gene therapy supply chain management. | Ms. Hagen has a technical background with degrees in cell and molecular biology and bioengineering, and experience as Chief Technical Officer at a biotechnology company and co-founder of a software platform company for cell and gene therapy supply chain management. |
| Filing Date | Source Excerpt |
|---|---|
| 2014-03-31 | Ms. Hagen earned her B.S. in cell and molecular biology, M.S. in bioengineering, and MBA at the University of Washington. |
| 2014-10-21 | Director Compensation table and related descriptions do not mention any software-related technical skills for Heidi Hagen. |
| 2015-03-25 | Ms. Hagen earned her B.S. in cell and molecular biology, M.S. in bioengineering, and MBA at the University of Washington. |
| 2016-03-18 | Ms. Hagen earned her B.S. in cell and molecular biology, M.S. in bioengineering, and MBA at the University of Washington. |
| 2017-03-20 | Ms. Hagen earned her B.S. in cell and molecular biology, M.S. in bioengineering, and MBA at the University of Washington. |
| 2018-03-22 | Ms. Hagen earned her B.S. in cell and molecular biology, M.S. in bioengineering, and MBA at the University of Washington. |
| 2019-03-20 | Ms. Hagen earned her B.S. in cell and molecular biology, M.S. in bioengineering, and MBA at the University of Washington. |
| 2020-03-20 | Ms. Hagen earned a B.S. in cell and molecular biology, M.S. in bioengineering, and MBA at the University of Washington. Since October 2015, Ms. Hagen has served as Chief Strategy Officer for Vineti, Inc., a privately-held company that develops and sells cloud-based software platforms for ordering, manufacturing and delivering personalized medicines. |
| 2021-03-19 | Ms. Hagen earned a B.S. in cell and molecular biology, M.S. in bioengineering, and M.B.A. at the University of Washington. The Board of Directors believes Ms. Hagen’s qualifications to serve on our Board of Directors include her leadership roles in the biotechnology industry in a wide range of positions, as well as her expertise in manufacturing, quality and other technical operations in the biotechnology and pharmaceutical space. Additionally, since October 2015, Ms. Hagen has served as Co-founder and Advisor (formerly Chief Strategy Officer) for Vineti, Inc., a privately-held company that develops and sells cloud-based software platforms for ordering, manufacturing and delivering personalized medicines. |
| 2022-03-17 | Ms. Hagen is also co-founder and former Chief Strategy Officer of Vineti, Inc., a software platform company for cell and gene therapy supply chain management. |
| 2023-03-23 | Ms. Hagen earned a B.S. in cell and molecular biology, M.S. in bioengineering, and M.B.A. at the University of Washington. |
| 2024-03-21 | Co-founder and Advisor and former Chief Strategy Officer of Vineti, Inc., a software platform company for cell and gene therapy supply chain management (2015-present). She also has a B.S. in cell and molecular biology, M.S. in bioengineering, and M.B.A. |
| 2025-03-20 | B.S. in cell and molecular biology, M.S. in bioengineering; Co-founder and Advisor and former Chief Strategy Officer of Vineti, Inc., a software platform company for cell and gene therapy supply chain management. |
Data sourced from SEC filings. Last updated: 2025-10-11